Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## Why UHC Denied an Immune Checkpoint Inhibitor as Experimental — and How to Appeal

UnitedHealthcare may categorize a specific use of a checkpoint inhibitor — pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), atezolizumab (Tecentriq), durvalumab (Imfinzi), or cemiplimab (Libtayo) — as "experimental, investigational, or unproven" when the requested indication, line of therapy, or combination regimen is not explicitly listed in UHC's coverage determination policy, even if the use has FDA approval or strong society guideline support. This type of denial is among the most commonly overturned on external review in oncology.

## Why This Denial Is Appealable

FDA-approved uses of checkpoint inhibitors are, by definition, not experimental — FDA approval requires substantial evidence of safety and effectiveness. Off-label uses supported by a compendia listing (such as NCCN, Micromedex, or DrugPoints) are separately protected under many state laws and, for Medicare Advantage plans, under CMS rules. Even uses not yet in compendia may be covered if your oncologist demonstrates the use is consistent with accepted medical practice. Under ACA §2719, you have the right to independent external review by a qualified oncologist who is not employed by UHC. External reviewers overturn experimental/investigational denials at high rates in oncology when the treating physician documents evidence-based support.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice (typically 180 days for non-urgent). UHC must decide within 30 days for pre-service standard appeals.
• Expedited review: Request expedited internal and external review simultaneously if treatment delay poses urgent health risk — decisions within 72 hours.
• External review (ACA §2719): After one internal denial (or if UHC fails to decide in time), you may request external review. The external reviewer must have oncology expertise appropriate to your cancer type.
• Compendia protection: If the use is listed in an approved compendia, cite the specific compendia listing in your appeal — this is often dispositive.
• State insurance department complaint: File simultaneously to create a regulatory record.

## Documentation to Gather

• FDA approval documentation: Attach the relevant approved indication from the FDA prescribing information showing the exact tumor type, histology, line of therapy, and any biomarker requirement for the requested use.
• NCCN or other compendia listing: Your oncologist should identify and attach the applicable NCCN guideline recommendation category for your specific tumor, stage, and biomarker profile.
• Oncologist letter of medical necessity: A detailed letter explaining why this agent is medically necessary for your specific case, why it is consistent with accepted oncologic practice, and why no equally effective covered alternative exists.
• Biomarker and pathology documentation: PD-L1 expression, MSI/dMMR, TMB, or other companion diagnostic results that support the specific indication.
• Prior treatment history: Documented list of prior therapies, lines of therapy, and outcomes.
• Peer-reviewed literature: Your oncologist may attach key publications supporting the use — focus on those cited in NCCN or other society guidelines.

## Criteria-Mapping Structure

Request UHC's coverage determination policy and respond to each "experimental" criterion:

| UHC Experimental Criterion | Your Documentation | |---|---| | Not FDA approved for this use | FDA label indication section attached | | Not in approved compendia | NCCN listing + category | | Insufficient clinical evidence | Oncologist letter + key literature | | Not accepted medical practice | Society guideline support | | Biomarker requirement not met | Companion diagnostic result |